abinScience | Recombinant Proteins, Antibodies & Assay Kits

African Swine Fever Virus (ASFV): Biological Mechanisms, Detection Technology Evolution, and Research Directions

This article systematically reviews the core biological characteristics, current research hotspots, and detection methods for ASFV. It elucidates the virus's complex structure, mechanisms of immunosuppression leading to high pathogenicity, and the emergence of recombinant strains, while also discussing vaccine strategies and key diagnostic targets.

Learn more

Breaking New Ground in Allergy Research: Precision Medicine and Global Collaboration Drive a $30 Billion Market

Allergy research is advancing toward a new era of precision medicine and immunotherapy, with innovations like CAR-T cell therapies offering solutions for severe allergies. The global allergy market is projected to reach $30 billion by 2030, fueled by growing demand for diagnostic and therapeutic tools. The World Allergy Organization (WAO) underscores the critical need for early diagnosis and prevention, collaborating with iCAALL to enhance global education and awareness. Researchers can partner with abinScience for tailored support, while distributors have a unique opportunity to expand their portfolios. Act now to join this transformative movement in allergy care and research!

Learn more

Understanding MERS-CoV: Structure, Pathogenesis, and Research Tools

This article explores Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a high-fatality pathogen first identified in 2012, focusing on its structure, pathogenesis, and vaccine development challenges. It highlights the virus’s spike protein and DPP4 receptor interaction, with recent Nature findings revealing a MERS-CoV-like mink coronavirus using ACE2, underscoring zoonotic risks (Wang et al., 2025). The article details immune responses, including IL-6, TNFα, IFNγ, and CRP-driven cytokine storms, and discusses vaccine hurdles like antibody-dependent enhancement. abinScience’s recombinant proteins and antibodies are presented as essential tools for virology and immunology research, empowering studies on MERS-CoV and related coronaviruses.

Learn more

Chikungunya Virus in 2025: A Global Health Threat and the Role of Innovative Research

Discover the Chikungunya virus (CHIKV) structure, key proteins, and pathogenesis, with insights from the 2025 Foshan outbreak and global epidemiology. Learn about WHO’s warnings on CHIKV epidemic risks and explore abinScience’s advanced research tools, including recombinant proteins and antibodies, designed to support vaccine and antiviral development for this mosquito-borne disease.

Learn more

Combating Mosquito-Borne Diseases: Research Tools and Insights

Uncover the science behind mosquito-borne diseases like Chikungunya’s crippling joint pain, Dengue’s complex serotypes, West Nile’s neurological risks, Yellow Fever’s historic threat, Zika’s congenital dangers, and Japanese Encephalitis’s brain inflammation. Learn about the challenges of controlling these viruses and explore cutting-edge lab tools for diagnostics, vaccine development, and research. abinScience offers specialized antibodies and recombinant proteins to target viral proteins, empowering scientists to fight these global health threats effectively.

Learn more

COVID-19 Resurgence in 2025: Omicron NB.1.8.1 Drives Surge with Enhanced Immune Escape

Since April 2025, China has faced a resurgence of COVID-19, with positivity rates in outpatient and inpatient settings rising sharply from 7.5% to 16.2% and 3.3% to 6.3%, respectively. Southern provinces report higher infection rates than the north, with the Omicron NB.1.8.1 variant driving the surge due to its enhanced immune escape capabilities. Symptoms remain mild, including sore throat, low-grade fever, and cough. The pandemic is expected to peak in late May and subside by late June. abinScience offers high-quality SARS-CoV-2-related proteins and antibodies to support cutting-edge virology research.

Learn more

InVivoMAb™ Plus: Precision In Vivo Antibodies for Animal Models by abinScience

The abinScience InVivoMAb™ Plus series offers over 400 high-quality in vivo antibodies, validated for purity, specificity, and functionality, ideal for research in cancer, autoimmune diseases, and infectious diseases. This page details the activity validation experiments and ELISA tests of anti-PD-1 and anti-PD-L1 antibodies in mouse models (B16-F10 and CT26), demonstrating significant tumor suppression and antigen-binding capabilities. The product list includes a range of antibodies and isotype controls designed for immune regulation and tumor immunotherapy, supported by batch stability and traceability.

Learn more

Understanding Hepatitis C Virus: Structure, Pathogenesis, Vaccine Research & abinScience Tools

Discover the biology, structure, and pathogenesis of Hepatitis C Virus (HCV), including its virion structure and immune evasion strategies. Explore the latest advances in HCV vaccine development and effective tools from abinScience, such as recombinant proteins and antibodies, to support antiviral research. Updated July 30, 2025, this resource offers insights into DAA therapy and vertical transmission challenges.

Learn more

Science Discovery: The Role of Erythropoietin (EPO) in Tumor Immune Evasion

Recent research has uncovered a critical role for erythropoietin (EPO) in tumor immune evasion. Tumor cells secrete EPO, which, through the EPOR signaling pathway, suppresses the immune function of macrophages, aiding tumors in escaping immune surveillance. Blocking the EPO/EPOR signaling enhances the efficacy of PD-1 immunotherapy, offering a novel strategy for cancer treatment.

Learn more

Tuberculosis Research and Scientific Applications in 2025: Advances in Diagnosis, Treatment, and Vaccines

This schematic illustration highlights four key research areas in tuberculosis (TB) studies: ESAT-6/CFP-10 as core antigens for immunodiagnostic platforms (IGRA, ELISPOT), HspX as a biomarker for latent infection and stress response, KatG and InhA as primary targets for drug resistance mechanism analysis, and Ag85 series antigens for vaccine target validation. Designed for scientific publications, this figure supports research in TB diagnostics, immune mechanisms, and drug resistance studies.

Learn more

Scientific ADA/PK Testing in Biosimilars: Value and Industry Trends

abinScience offers high-sensitivity ADA/PK assay kits designed for research-use ELISA platforms, adhering to FDA, EMA, and ICH standards. Ideal for immunogenicity and pharmacokinetics studies in biopharmaceutical development, our ISO 9001-certified kits support global research with unparalleled sensitivity and reproducibility. Explore our range of assay kits for biosimilars like Adalimumab and Trastuzumab, optimized for accurate data in preclinical and regulatory studies.

Learn more

LRP8 Identified as a Critical Receptor for Tick-Borne Encephalitis Virus via Genome-Wide CRISPR Screening

A genome-wide CRISPR-Cas9 screen has identified low-density lipoprotein receptor-related protein 8 (LRP8, also known as ApoER2) as a key receptor required for tick-borne encephalitis virus (TBEV) infection. The study reveals that LRP8 directly mediates TBEV attachment and endocytosis through its LA1–2 domains, promoting viral entry and replication. Furthermore, a soluble LRP8(LA1–2)-Fc decoy protein was engineered to block TBEV infection both in vitro and in vivo, fully protecting mice from lethal challenge. These findings establish LRP8 as a critical host factor and a promising therapeutic target for antiviral intervention.

Learn more

Recombinant Proteins

Antibodies

Assay Kits

Browse by products

Featured content

About abinScience

News

Quick access

Contact Us